{
    "name": "vecuronium",
    "comment": "Rx",
    "other_names": [
        "Norcuron"
    ],
    "classes": [
        "Neuromuscular Blockers",
        "Nondepolarizing"
    ],
    "source": "https://reference.medscape.com/drug/vecuronium-343110",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Not known if excreted in breast milk; effect on nursing infant not known; used during pregnancy only when clearly needed"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Not known if excreted in breast milk; effect on nursing infant not known; used during pregnancy only when clearly needed"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "The drug should be administered only by adequately trained individuals familiar with its actions, characteristics, and hazards"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Lack of ventilatory support",
                "Neuromuscular disease"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Additive/synergistic effects if administered with or following an opioid, sedative or anesthetic agent",
                "Severe anaphylactic reactions to neuromuscular blocking agents have been reported; these reactions have, in some cases, been life threatening and fatal; because of the potential severity of these reactions, the necessary precautions, such as the immediate availability of appropriate emergency treatment, should be taken; neuromuscular cross-sensitivity with other nuromuscular blocking agents possible",
                "Some patients may experience prolonged recovery (paralysis) of neuromuscular function",
                "Adequate ventilatory support mandatory, may experience resistance with >25% TBSA burns, may experience increased sensitivity with electrolyte disorders (hyperMg, hypoK, hypoCa)",
                "CAUTION: Hepatobiliary obstruction, renal dysfunction will significantly prolong duration of action"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dantrolene",
            "description": {
                "common": "dantrolene, vecuronium.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. May potentiate vecuronium-induced neuromuscular block."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amikacin",
            "description": {
                "common": "amikacin increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amphotericin B deoxycholate",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen, vecuronium.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "capreomycin",
            "description": {
                "common": "capreomycin increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clindamycin",
            "description": {
                "common": "clindamycin increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "colistin",
            "description": {
                "common": "vecuronium increases effects of colistin by pharmacodynamic synergism. Avoid or Use Alternate Drug. Potentiation of neuromuscular blockade; risk of respiratory arrest."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "demeclocycline",
            "description": {
                "common": "demeclocycline increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxycycline",
            "description": {
                "common": "doxycycline increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fentanyl",
            "description": {
                "common": "fentanyl, vecuronium.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fentanyl intranasal",
            "description": {
                "common": "fentanyl intranasal, vecuronium.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fentanyl transdermal",
            "description": {
                "common": "fentanyl transdermal, vecuronium.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fentanyl transmucosal",
            "description": {
                "common": "fentanyl transmucosal, vecuronium.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gentamicin",
            "description": {
                "common": "gentamicin increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydrocodone",
            "description": {
                "common": "hydrocodone, vecuronium.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lincomycin",
            "description": {
                "common": "lincomycin increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "minocycline",
            "description": {
                "common": "minocycline increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "neomycin PO increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omadacycline",
            "description": {
                "common": "omadacycline increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxytetracycline",
            "description": {
                "common": "oxytetracycline increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "paromomycin",
            "description": {
                "common": "paromomycin increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "polymyxin B",
            "description": {
                "common": "polymyxin B increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pramlintide",
            "description": {
                "common": "pramlintide, vecuronium.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinine",
            "description": {
                "common": "quinine increases effects of vecuronium by pharmacodynamic synergism. Contraindicated. Risk of resp. depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sarecycline",
            "description": {
                "common": "sarecycline increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "streptomycin",
            "description": {
                "common": "streptomycin increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sufentanil SL",
            "description": {
                "common": "sufentanil SL, vecuronium.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetracycline",
            "description": {
                "common": "tetracycline increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tobramycin",
            "description": {
                "common": "tobramycin increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "valerian",
            "description": {
                "common": "valerian and vecuronium both increase  sedation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abobotulinumtoxinA",
            "description": {
                "common": "vecuronium increases effects of abobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Neuromuscular blockers may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aclidinium",
            "description": {
                "common": "aclidinium and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "vecuronium and amitriptyline both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "vecuronium and amoxapine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anticholinergic/sedative combos",
            "description": {
                "common": "anticholinergic/sedative combos and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "vecuronium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atracurium",
            "description": {
                "common": "atracurium and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atropine",
            "description": {
                "common": "atropine and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atropine IV/IM",
            "description": {
                "common": "atropine IV/IM and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belladonna alkaloids",
            "description": {
                "common": "belladonna alkaloids and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belladonna and opium",
            "description": {
                "common": "belladonna and opium and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benperidol",
            "description": {
                "common": "vecuronium decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betamethasone",
            "description": {
                "common": "vecuronium, betamethasone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bethanechol",
            "description": {
                "common": "bethanechol increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "vecuronium increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbachol",
            "description": {
                "common": "carbachol increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cevimeline",
            "description": {
                "common": "cevimeline increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "vecuronium decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisatracurium",
            "description": {
                "common": "cisatracurium and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "vecuronium and clomipramine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "vecuronium decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "corticotropin",
            "description": {
                "common": "vecuronium, corticotropin. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cortisone",
            "description": {
                "common": "vecuronium, cortisone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclizine",
            "description": {
                "common": "cyclizine and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "cyclobenzaprine and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darifenacin",
            "description": {
                "common": "darifenacin and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "vecuronium, deflazacort. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "vecuronium and desipramine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "vecuronium, dexamethasone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dicyclomine",
            "description": {
                "common": "dicyclomine and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "diphenhydramine and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "donepezil",
            "description": {
                "common": "donepezil increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "donepezil transdermal",
            "description": {
                "common": "donepezil transdermal and vecuronium both increase  pharmacodynamic synergism. Use Caution/Monitor. Donepezil transdermal, a cholinesterase inhibitor, may potentiate the effects on muscle relacation during anesthesia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dosulepin",
            "description": {
                "common": "vecuronium and dosulepin both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxapram",
            "description": {
                "common": "doxapram decreases effects of vecuronium by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "vecuronium and doxepin both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "droperidol",
            "description": {
                "common": "vecuronium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "echothiophate iodide",
            "description": {
                "common": "echothiophate iodide increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fesoterodine",
            "description": {
                "common": "fesoterodine and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flavoxate",
            "description": {
                "common": "flavoxate and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "vecuronium, fludrocortisone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "vecuronium decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin decreases effects of vecuronium by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Monitor closely for more rapid recovery from neuromuscular blockade than expected; infusion rate requirements may be higher."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "galantamine",
            "description": {
                "common": "galantamine increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glycopyrrolate",
            "description": {
                "common": "glycopyrrolate and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glycopyrrolate inhaled",
            "description": {
                "common": "glycopyrrolate inhaled and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "vecuronium decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "henbane",
            "description": {
                "common": "henbane and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "homatropine",
            "description": {
                "common": "homatropine and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "huperzine A",
            "description": {
                "common": "huperzine A increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "vecuronium, hydrocortisone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyoscyamine",
            "description": {
                "common": "hyoscyamine and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyoscyamine spray",
            "description": {
                "common": "hyoscyamine spray and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "vecuronium decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "vecuronium and imipramine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ipratropium",
            "description": {
                "common": "ipratropium and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofepramine",
            "description": {
                "common": "vecuronium and lofepramine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine",
            "description": {
                "common": "vecuronium decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "loxapine inhaled increases effects of vecuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium sulfate",
            "description": {
                "common": "magnesium sulfate increases effects of vecuronium by pharmacodynamic synergism. Use Caution/Monitor. Interaction occurs with parenteral magnesium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium supplement",
            "description": {
                "common": "magnesium supplement, vecuronium.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maprotiline",
            "description": {
                "common": "vecuronium and maprotiline both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclizine",
            "description": {
                "common": "meclizine and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methscopolamine",
            "description": {
                "common": "methscopolamine and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "vecuronium, methylprednisolone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "neostigmine",
            "description": {
                "common": "neostigmine increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "vecuronium and nortriptyline both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "vecuronium decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "oliceridine, vecuronium.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "onabotulinumtoxinA",
            "description": {
                "common": "onabotulinumtoxinA and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orphenadrine",
            "description": {
                "common": "vecuronium and orphenadrine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin",
            "description": {
                "common": "oxybutynin and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin topical",
            "description": {
                "common": "oxybutynin topical and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin transdermal",
            "description": {
                "common": "oxybutynin transdermal and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxycodone",
            "description": {
                "common": "oxycodone increases effects of vecuronium by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Oxycodone may enhance the neuromuscular blocking action of true skeletal muscle relaxants and produce an increased degree of respiratory depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paliperidone",
            "description": {
                "common": "vecuronium decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pancuronium",
            "description": {
                "common": "pancuronium and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "vecuronium decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin decreases effects of vecuronium by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Monitor closely for more rapid recovery from neuromuscular blockade than expected; infusion rate requirements may be higher."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "physostigmine",
            "description": {
                "common": "physostigmine increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pilocarpine",
            "description": {
                "common": "pilocarpine increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "vecuronium decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "piperacillin",
            "description": {
                "common": "piperacillin increases toxicity of vecuronium by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Neuromuscular blockade may be prolonged."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pralidoxime",
            "description": {
                "common": "pralidoxime and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisolone",
            "description": {
                "common": "vecuronium, prednisolone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisone",
            "description": {
                "common": "vecuronium, prednisone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "vecuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "promethazine",
            "description": {
                "common": "vecuronium decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propantheline",
            "description": {
                "common": "propantheline and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "vecuronium and protriptyline both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pyridostigmine",
            "description": {
                "common": "pyridostigmine increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "vecuronium decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rapacuronium",
            "description": {
                "common": "rapacuronium and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "vecuronium decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rocuronium",
            "description": {
                "common": "rocuronium and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "scopolamine",
            "description": {
                "common": "scopolamine and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "sevoflurane increases levels of vecuronium by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases effects of vecuronium by Other (see comment). Use Caution/Monitor. \nComment: Magnesium may potentiate the effects of the neuromuscular blocking agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases effects of vecuronium by Other (see comment). Use Caution/Monitor. \nComment: Magnesium may potentiate the effects of the neuromuscular blocking agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solifenacin",
            "description": {
                "common": "solifenacin and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "succinylcholine",
            "description": {
                "common": "succinylcholine increases and vecuronium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "vecuronium decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiothixene",
            "description": {
                "common": "vecuronium decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tiotropium",
            "description": {
                "common": "tiotropium and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled increases effects of vecuronium by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Aminoglycosides may aggravate muscle weakness because of a curare-like effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolterodine",
            "description": {
                "common": "tolterodine and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "vecuronium and trazodone both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "vecuronium, triamcinolone acetonide injectable suspension. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "vecuronium decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "vecuronium and trimipramine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trospium chloride",
            "description": {
                "common": "trospium chloride and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "vecuronium decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zotepine",
            "description": {
                "common": "vecuronium decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amlodipine",
            "description": {
                "common": "amlodipine increases effects of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clevidipine",
            "description": {
                "common": "clevidipine increases effects of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clonazepam",
            "description": {
                "common": "clonazepam decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diazepam",
            "description": {
                "common": "diazepam decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diltiazem",
            "description": {
                "common": "diltiazem increases effects of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dimenhydrinate",
            "description": {
                "common": "dimenhydrinate increases toxicity of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "donepezil",
            "description": {
                "common": "donepezil decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "ethosuximide decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "felbamate",
            "description": {
                "common": "felbamate decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "felodipine",
            "description": {
                "common": "felodipine increases effects of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gabapentin",
            "description": {
                "common": "gabapentin decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gabapentin enacarbil",
            "description": {
                "common": "gabapentin enacarbil decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "galantamine",
            "description": {
                "common": "galantamine decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isradipine",
            "description": {
                "common": "isradipine increases effects of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lacosamide",
            "description": {
                "common": "lacosamide decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lamotrigine",
            "description": {
                "common": "lamotrigine decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levetiracetam",
            "description": {
                "common": "levetiracetam decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lithium",
            "description": {
                "common": "lithium increases effects of vecuronium by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lorazepam",
            "description": {
                "common": "lorazepam decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methsuximide",
            "description": {
                "common": "methsuximide decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nicardipine",
            "description": {
                "common": "nicardipine increases effects of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nifedipine",
            "description": {
                "common": "nifedipine increases effects of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "nisoldipine increases effects of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine increases effects of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rufinamide",
            "description": {
                "common": "rufinamide decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thiamine",
            "description": {
                "common": "thiamine increases effects of vecuronium by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tiagabine",
            "description": {
                "common": "tiagabine decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "topiramate",
            "description": {
                "common": "topiramate decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "valproic acid",
            "description": {
                "common": "valproic acid decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "verapamil",
            "description": {
                "common": "verapamil increases effects of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zonisamide",
            "description": {
                "common": "zonisamide decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Skeletal muscle weakness or paralysis",
            "percent": null
        },
        {
            "name": "Respiratory insufficiency or apnea",
            "percent": null
        },
        {
            "name": "Hypersensitivity reactions associated with histamine release",
            "percent": null
        },
        {
            "name": "e",
            "percent": null
        },
        {
            "name": "g",
            "percent": null
        },
        {
            "name": "bronchospasm",
            "percent": null
        },
        {
            "name": "flushing",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "acute urticaria",
            "percent": null
        },
        {
            "name": "hypotension",
            "percent": null
        },
        {
            "name": "tachycardia",
            "percent": null
        },
        {
            "name": "Itching",
            "percent": null
        },
        {
            "name": "Myositis ossificans",
            "percent": null
        },
        {
            "name": "prolonged use",
            "percent": null
        },
        {
            "name": "Acute quadriplegic myopathy syndrome",
            "percent": null
        },
        {
            "name": "prolonged use",
            "percent": null
        },
        {
            "name": "Less cardiovascular effects than pancuronium or atracurium",
            "percent": null
        }
    ]
}